pharma · Congenital Adrenal Hyperplasia · Polycystic Ovary Syndrome · SPRB
SPRUCE BIOSCIENCES
SPRUCE BIOSCIENCES, INC.
Spruce Biosciences is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker SPRB. Primary therapeutic focus areas include Congenital Adrenal Hyperplasia, Polycystic Ovary Syndrom
South San Francisco, USA HQ
2016 Founded
27 Employees
Public company Type
SPRB · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2016
- Employees
- 27
- Programs
- 5
- Drugs
- 3
- Patents
- 9
Tildacerfont/Placebo
Phase 2 · small molecule · Congenital Adrenal Hyperplasia
Tildacerfont/Placebo for Congenital Adrenal Hyperplasia is a Phase 2 program (small_molecule) at SPRUCE BIOSCIENCES, INC. with 2 ClinicalTrials.gov record(s).
Internal code SPR001-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- SPRUCE BIOSCIENCES, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Congenital Adrenal Hyperplasia
- Status
- terminated
- Trials
- 2